Pronethalol

Pronethalol ((±) -Pronethalo) is a non-selective β-adrenergic antagonist. Pronethalol is a potent inhibitor of Sox2 expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias and limits the cerebral arteriovenous malformation (AVMs) [1][2].

Product Specifications

CAS Number

[54-80-8]

Product Name Alternative

(±) -Pronethalo

UNSPSC

12352005

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Pronethalol.html

Purity

99.88

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC(CNC(C)C)C1=CC=C2C=CC=CC2=C1

Molecular Formula

C15H19NO

Molecular Weight

229.32

References & Citations

[1]Jiayi Yao, et al. Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations. J Clin Invest. 2019 Jun 24;129 (8) :3121-3133.|[2]Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71 (4) :503-508.|[3]Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71 (4) :503-8.